



PTO/SB/08B (08-03)  
Approved for use through 7/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/829,137
		Filing Date	April 21, 2004
		First Named Inventor	Gevas et al.
		Group Art Unit	unassigned
Examiner Name	unassigned	Attorney Docket Number	ACG2BUSA
Sheet	1	of	10

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
MW	AA	US-3,931,141	01-06-1976	Wissmann	
	AB	US-4,069,313	01-17-1978	Woodhour	
	AC	US-4,201,770	05-06-1980	Stevens	
	AD	US-4,384,995	05-24-1983	Stevens	
	AE	US-4,526,716	07-02-1985	Stevens	
	AF	US-4,565,805	01-21-1986	Smirnov	
	AG	US-4,687,759	08-18-1987	Martinez	
	AH	US-4,691,006	09-01-1987	Stevens	
	AI	US-4,894,443	01-16-1990	Greenfield	
	AJ	US-5,023,077	06-11-1991	Gevas	
	AK	US-5,120,829	06-09-1992	Pierschbacher	
MW	BA	US-5,256,542	10-26-1993	Chang	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
MW	AL	EP-380 230	08-01-1990	Gevas		
	AM	WO-97/28821	08-14-1997	Gevas		
MW	AN	WO-99/59628	11-25-1999	Gevas		

Examiner Signature		Date Considered	04/06
--------------------	--	-----------------	-------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

-Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	2	of	10	Attorney Docket Number	ACG2BUSA

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
mm	BB	US-5,468,494	11-21-1995	Gevas	
	BC	US-5,607,676	03-04-1997	Gevas	
	BD	US-5,609,870	03-11-1997	Gevas	
	BE	US-5,622,702	04-22-1997	Gevas	
	BF	US-5,668,117	09-16-1997	Shapiro	
	BG	US-5,785,970	07-28-1998	Gevas	
	BH	US-5,866,128	02-02-1999	Gevas	
	BI	US-2003-0068326-A1	04-10-2003	Gevas	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

* Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/829,137		
		Filing Date	April 21, 2004		
		First Named Inventor	Gevas et al.		
		Group Art Unit	unassigned		
Examiner Name	unassigned				
Sheet	3	of	10	Attorney Docket Number	ACG2BUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
ms	AR	ANTONSON et al., "High doses of histamine antagonists do not prevent relapses of peptic esophagitis following therapy with a proton pump inhibitor", <i>Gastroenterology</i> May 1990 98(5/2):A16 [Abstract]	
	AS	ARCHAMBAULT et al., "Influence of immunomodulatory agents on bovine humoral and cellular immune responses to parenteral inoculation with bovine rotavirus vaccines", <i>Vet. Microbiol.</i> August 1988 17:323-334	
	AT	AZUMA et al., "Immunocytochemical evidence for differential distribution of gastrin forms using region-specific monoclonal antibodies", <i>Gastroenterologica Japonica</i> August 1986 21(4):319-324	
	AU	BARDHAN et al., "The safety of long-term cimetidine treatment", <i>Gastroenterology</i> May 1990 98(5/2):A18 [Abstract]	
	AV	BEACHAM et al., "Structures of human gastrins I and II", <i>Nature</i> February 1966 209(5023):583-586	
	AW	BEAUCHAMP et al., "Proglumide, a gastrin receptor antagonist, inhibits growth of colon cancer and enhances survival in mice", <i>Ann. Surg.</i> September 1985 202(3):303-309	
	AX	BOOTH et al., "Acid clearing from the distal esophagus", <i>Arch. Surg.</i> May 1968 96:731-734	
	AY	BOWIE et al., "Deciphering the message in protein sequences: Tolerance to amino acid substitutions", <i>Science</i> March 1990 247:1306-1310	
	AZ	BRINTON et al., "Cancer risk following pernicious anaemia", <i>Br. J. Cancer</i> May 1989 59(5):810-813	
ms	AAR	BUDAVARI et al., The Merck Index (11th ed.), Rahway, New Jersey, Merck & Co., 1989 p. 1082	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

-Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/829,137		
		Filing Date	April 21, 2004		
		First Named Inventor	Gevas et al.		
		Group Art Unit	unassigned		
		Examiner Name	unassigned		
Sheet	4	of	10	Attorney Docket Number	ACG2BUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>mw</i>	AAS	CHOUDHURY et al., "N-Terminal sequence of human big gastrin: Sequence, synthetic and immunochemical studies", <i>A76Hoppe-Seyler's Z. Physiol. Chem.</i> <b>November 1980</b> 361:1719-1733	
	AAT	CUNNINGHAM et al., "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis", <i>Science</i> <b>June 1989</b> 244:1081-1085	
	AAU	DE MAGISTRIS et al., "A simple enzymatic procedure for radioimmunochemical quantitation of the large molecular forms of gastrin and cholecystokinin", <i>Analytical Biochem.</i> <b>February 1980</b> 102:126-133	
	AAV	DEMEESTER et al., "Patterns of gastroesophageal reflux in health and disease", <i>Ann. Surg.</i> <b>October 1976</b> 184(4):459-470	
	AAW	DEVAULT et al., "Current diagnosis and treatment of gastroesophageal reflux disease", <i>Mayo Clin. Proc.</i> <b>September 1994</b> 69(9):867-876	
	AAX	DOCKRAY et al., "Amino terminal gastrin fragment in serum of Zollinger-Ellison syndrome patients", <i>Gastroenterology</i> <b>February 1975</b> 68(2):222-230	
	AAV	DOCKRAY et al., "Heptadecapeptide gastrin: measurement in blood by specific radioimmunoassay", <i>Gastroenterology</i> <b>December 1976</b> 71(6):971-977	
	AAZ	DOCKRAY et al., "Immunochemical studies on big gastrin using NH <sub>2</sub> -terminal specific antisera", <i>Chemical Abstracts</i> <b>1981</b> 94:506-507 [Abstract# 94:119200w]	
	BR	DOCKRAY, G., "Immunochemical studies on big gastrin using NH <sub>2</sub> -terminal specific antisera", <i>Regulatory Peptides</i> <b>December 1980</b> 1:169-186	
	BS	FENNERTY et al., "Medical therapy for gastroesophageal reflux disease", <i>Arch. Intern. Med.</i> <b>December 1991</b> 151(12):2365-2366	
<i>mw</i>	BT	FESTEN et al., "Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels", <i>Gastroenterology</i> <b>November 1984</b> 87(5):1030-1034	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

-Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/829,137		
		Filing Date	April 21, 2004		
		First Named Inventor	Gevas et al.		
		Group Art Unit	unassigned		
Examiner Name	unassigned				
Sheet	5	of	10	Attorney Docket Number	ACG2BUSA

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>MA</i>	BU	FLYNN et al., "Modulation of T-cell reactivity to synthetic peptide analogues of foot-and-mouth disease virus in sheep by amino acid substitutions", <i>Vet. Immunol. Immunopath.</i> March 1992 31:255-266	
	BV	FRESTON et al., "Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective", <i>Am. J. Gastroenterol.</i> April 1997 92(4):51S-57S [Supplement]	
	BW	GEVAS et al., "Prevention and treatment of hypergastrinemia", <i>U.S. Patent App. No. 09/700,329</i> , filed February 8, 2001	
	BX	GREGORY et al., "Isolation of two gastrins from human antral mucosa", <i>Nature</i> February 1966 209(5023):583	
	BY	HALTER et al., "Evaluation of a monoclonal anti-gastrin antibody as a tool for immunoneutralization of gastrin during omeprazole in treatment in a rat", <i>Gastroenterology</i> 1989 96(5):A194 [Abstract]	
	BZ	HOUGHTEN et al., "Relative importance of position and individual amino acid residues in peptide antigen-antibody interactions: Implications in the mechanism of antigenic drift and antigenic shift", <i>Vaccines</i> 86 (Ed. F. Brown et al.) 1986 Cold Spring Harbor Laboratory: 21-25	
	BBR	HUGHES et al., "Therapy with gastrin antibody in the Zollinger-Ellison Syndrome", <i>Digestive Disease</i> March 1976 21(3):201-204	
	BBS	IWANAGA et al., "Immunocytochemical localization of the different gastrin forms in the pyloric antrum", <i>Biomed. Res.</i> 1980 1:316-320	
<i>MA</i>	BBT	JAFFE et al., "Gastrin resistance following immunization to the C-terminal tetrapeptide amide of gastrin", <i>Surgery</i> February 1971 69(2):232-237	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

-Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	6	of	10	Attorney Docket Number	ACG2BUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BBU	JAFFE et al., "Inhibition of endogenous gastrin activity by antibodies to the carboxyl-terminal tetrapeptide amide of gastrin", <i>Gastroenterology</i> February 1970 58(2):151-156	
	BBV	JAFFE et al., "Inhibition of gastrin activity by incubation with antibodies to the C-terminal tetrapeptide of gastrin", <i>Surgery</i> April 1969 65(4):633-639	
	BBW	JANSEN et al., "Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis", <i>Gastroenterology</i> September 1990 99(3):621-628	
	BBX	JONES et al., "Peptide vaccines derived from a malarial surface antigen: effects of dose and adjuvants on immunogenicity", <i>Immunology Letters</i> July 1990 24:253-260	
	BBY	KOTHARY et al., "NH2-terminal of gastrin-17 in duodenal ulcer disease: Identification of progastrin-17", <i>Biochem. Biophys. Res. Comm.</i> July 1987 146(2):884-888	
	BBZ	KUIPERS et al., "Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication", <i>New. Eng. J. Med.</i> April 1996 334(16):1018-1022	
	CR	KUSYK et al., "Stimulation of growth of a colon cancer cell line by gastrin", <i>Am. J. Physiol.</i> November 1986 251:G597-G601	
	CS	LAMERS et al., "Role of gastrin and cholecystokinin in tumors of the gastrointestinal tract", <i>Eur. J. Cancer Clin. Oncol.</i> February 1988 24(2):267-273	
	CT	LAMOTE et al., "Stimulating effect of pentagastrin on cancer cell proliferation kinetics in chemically induced colon cancer in rats", <i>Regulatory Peptides</i> January 1988 20:1-9	
	CU	LARSSON et al., "Characterization of antral gastrin cells with region-specific antisera", <i>J. histochem. Cytochem.</i> December 1977 25(12):1317-1321	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

-Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/829,137		
		Filing Date	April 21, 2004		
		First Named Inventor	Gevas et al.		
		Group Art Unit	unassigned		
Examiner Name	unassigned				
Sheet	7	of	10	Attorney Docket Number	ACG2BUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
MM	CV	LARSSON, L, "Histochemistry of gastrin cells", <i>Neurohistochem.: Modern Meth. And App.</i> 1986 Alan R. Liss, Inc.: 527-567	
	CW	MAKISHIMA et al., "Active immunization against gastrin-17 with an N-terminal derived immunogen inhibits gastric and duodenal lesions in rats", <i>Gastroenterology</i> April 1994 106(4/2):A824 [Abstract]	
	CX	MCCLOY et al., "Pathophysiological effects of long-term acid suppression in man", <i>Dig. Dis. And Sciences</i> February 1995 40(2):96S-120S [Supplement]	
	CY	MCGREGOR et al., "Trophic effects of gastrin on colorectal neoplasms in the rat", <i>Ann. Surg.</i> February 1982 195(2):219-223	
	CZ	MORODER et al., "Gastrins and cholecystokinins: Chemical and immunological aspects", <i>Gastrin and Cholecystokinin, Chem., Physio. And Pharma.</i> (Ed. J. Bali et al.) 1987 Elsevier Science Publishers B.V.: 21-32	
	CCR	NEMETH et al., "A gastrin aminoterminalis 1-13 fragmensevel kidolgozott, szekvenciaspecifikus radioimmunoassay", <i>Izotoptechnika</i> 1982 25(4):288-294	
	CCS	NEMETH et al., "Development of a sequence-specific radioimmunoassay by using N-terminal gastrin 1-13 antibody", <i>Chemical Abstracts</i> 1983 98:495 [Abstract# 98:51653w]	
	CCT	PALMER SMITH et al., "Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer", <i>Gastroenterology</i> December 1988 95(6):1541-1548	
	CCU	PALMER SMITH et al., "Elevated gastrin levels in patients with colon cancer or adenomatous polyps", <i>Dig. Diseases. And Sci.</i> February 1989 34(2):171-174	
MM	CCV	PAWLIKOWSKI et al., "Gastrin and somatostatin levels in patients with gastric cancer", <i>Horm. Metabol. Res.</i> February 1989 21:89-91	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

•Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/829,137		
		Filing Date	April 21, 2004		
		First Named Inventor	Gevas et al.		
		Group Art Unit	unassigned		
		Examiner Name	unassigned		
Sheet	8	of	10	Attorney Docket Number	ACG2BUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>my</i>	CCW	POWER et al., "A novel gastrin-processing pathway in mammalian antrum", <i>Chemical Abstracts</i> August 1988 109(9):113 [Abstract# 109:67341z]	
	CCX	RAE-VENTER et al., "Gastrin receptors in human colon carcinoma", <i>Gastroenterology</i> 1986 80(5/2):1256 [Abstract]	
	CCY	REHFELD et al., "Production and evaluation of antibodies for the radioimmunoassay of gastrin", <i>Scnad. J. Clin. Lab. Invest.</i> October 1972 30:221-232	
	CCZ	REHFELD et al., "Sulfation of gastrin: Effect on immunoreactivity", <i>Regulatory Peptides</i> September 1981 2:333-342	
	DR	SABESIN et al., "Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations", <i>Arch. Intern. Med.</i> December 1991 151(12):2394-2400	
	DS	SIEMANN, D., "Satisfactory and unsatisfactory tumor models: Factors influencing the selection of a tumor model for experimental evaluation", <i>Rodent Tumor Models in Experimental Cancer Therapy</i> (Ed. Kallman) 1987 Pergamon Press, NY: 12-15	
	DT	SOBHANI et al., "Chronic endogenous hypergastrinemia in humans: Evidence for a mitogenic effect on the colonic mucosa", <i>Gastroenterology</i> July 1993 105(1):22-30	
	DU	SONTAG et al., "Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The US Multicenter Study", <i>Gastroenterology</i> January 1992 102(1):109-118	
	DV	SUGANO et al., "Identification and characterization of glycine-extended post-translational processing intermediates of progastrin in porcine stomach", <i>J. Bio. Chem.</i> September 1986 260(21):11724-11729	
<i>mm</i>	DW	SUMII et al., "Regulation of antral peptides by administration of omeprazole to healthy men", <i>Am. J. Gastroenterol.</i> November 1994 89(11):2033-2037	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/829,137		
		Filing Date	April 21, 2004		
		First Named Inventor	Gevas et al.		
		Group Art Unit	unassigned		
Examiner Name	unassigned				
Sheet	9	of	10	Attorney Docket Number	ACG2BUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>mm</i>	DX	SUNDLER et al., "The neuroendocrine system of the gut--an update", <i>Acta Oncologica</i> 1991 30(4):419-427	
	DY	TALLEY et al., "Risk for colorectal adenocarcinoma in pernicious anemia", <i>Annals of Internal Medicine</i> November 1989 111(9):738-742	
	DZ	THORNDYKE et al., "Identification and localization of material with gastrin-like immunoreactivity in the neural ganglion of a protochordate, <i>Ciona intestinalis</i> ", <i>Regulatory Peptides</i> December 30, 1986 16:269-279	
	DDR	TIELEMANS et al., "Proliferation of enterochromaffinlike cells in omeprazole-treated hypergastrinemic rats", <i>Gastroenterology</i> March 1989 96(3):723-729	
	DDS	UPP et al., "Clinical significance of gastrin receptors in human colon cancers", <i>Cancer Res.</i> January 1989 49:488-492	
	DDT	UPP et al., "Polyamine levels and gastrin receptors in colon cancers", <i>Ann. Surg.</i> June 1988 207(6):662-669	
	DDU	VARNDELL et al., "Intracellular topography of immunoreactive gastrin demonstrated using electron immunocytochemistry", <i>Experientia</i> July 15, 1983 39:713-717	
	DDV	VARRO et al., "Pathways of processing of the gastrin precursor in rat antral mucosa", <i>J. Clin. Invest.</i> April 1995 95:1642-1649	
	DDW	WANG et al., "Processing and proliferative effects of human progastrin in transgenic mice", <i>J. Clin. Invest.</i> October 1996 98(8):1918-1929	
	DDX	WATSON et al., "Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5", <i>Int. J. Cancer</i> April 10, 1995 61:233-240	
<i>mm</i>	DDY	WATSON et al., "Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer", <i>Cancer Res.</i> February 15, 1996 56:880-885	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,137
				Filing Date	April 21, 2004
				First Named Inventor	Gevas et al.
				Group Art Unit	unassigned
				Examiner Name	unassigned
Sheet	10	of	10	Attorney Docket Number	ACG2BUSA

## NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
MM	DDZ	WATSON et al., "Growth-promoting action of gastrin on human colonic and gastric tumour cells cultured in vitro", <i>Br. J. Surg.</i> April 1988 75(4):342-345 [Abstract]	
	ER	WATSON et al., "Pre-clinical evaluation of the gastrin-immune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model", <i>Int. J. Cancer</i> March 16, 1998 75:873-877	
	ES	WEINSTOCK et al., "Binding of gastrin(17) to human gastric carcinoma cell lines", <i>Cancer Res.</i> February 1988 48(4):932-937 [Abstract]	
	ET	WENDLBERGER et al., "The syntheses of human big gastrin I and its 32-leucine analog", <i>Chemical Abstracts</i> May 1980 92(21):722 [Abstract# 92:198749s]	
	EU	WUNSCH et al., "Biological and immunological properties of human gastrin I analogues", <i>Hoppe-Syler's Z. Physiol. Chem.</i> June 1982 363:665-669	
	EV	YAMAGUCHI et al., "Amino-terminal immunoreactivity of big gastrin in plasma and tumors obtained from patients with Zollinger-Ellison Syndrome", <i>Chem. Abstracts</i> 1984 100:373 [Abstract# 100:154661m]	
	EW	YANAIHARA et al., "A new type of gastrin derivative and its use for production of central region-specific anti-gastrin sera", <i>Biomedical Research</i> 1980 1:242-247	
	EX	YANAIHARA et al., "Human big gastrin N-terminal fragment immunoreactivity", <i>Gut Peptides</i> (Ed. A. Miyoshi) 1979 Elsevier/North-Holland Biomedical Press: 26-33	
MM	EY	ZEITOUN, P., "Comparison of omeprazole with ranitidine in the treatment of reflux oesophagitis", <i>Scand. J. Gastroenterol.</i> 1989 166:83-87	

Examiner Signature		Date Considered	04/27
--------------------	---	-----------------	-------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.